1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04U.534, NCT00328510
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001M2301, NCT00789828
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0825, RTOG 0825, NCT00884741
|
|
4.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0577, N0577, NCT00887146
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EF-14, NCT00916409
|
|
6.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E3F05, E3F05, NCT00978458
|
|
7.
|
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 2009-0232, NCT01014767
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0272, N0272, NCT00049127
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-05103, 05103, UCSF-H41995-27311-01, NCT00293423
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0063, NCI-P6680, NCT00293566
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0572, N0572, NCT00329719
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 501007705, NCT00301418
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ABTC-05-02, NABTC-05-02, NCT00335764
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ABTC-0504, NABTT-0504, NABTT-0504, NCT00379080
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 021-003, NCT00394628
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-377, IRUSZACT0018, NCT00441142
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: 2006P-000464, NCT00456612
|
|
21.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ABTC-0603, NABTT-0603, 0603, NCT00486603
|
|
22.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0604104, OSI3781s, NCT00509431
|
|
23.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NU07C1, NU 07C1, NCT00516282
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 007, NCT00528684
|
|
25.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N057K, N057K, NCT00553150
|
